EcoDrugPlus

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Gamma

Ensembl ID : ENSATEG00000003954
Gene Symbol: PIK3CG
2 Cross references
216 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSATEG00000017874
Gene Symbol: PDE10A
3 Cross references
207 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSATEG00000016190
Gene Symbol: PDE3A
4 Cross references
185 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSATEG00000007413
Gene Symbol: PDE3B
3 Cross references
204 Possible Orthologues:

Phosphodiesterase 4a, Camp-Specific

Ensembl ID : ENSATEG00000021004
Gene Symbol: PDE4A
2 Cross references
187 Possible Orthologues:

Phosphodiesterase 4b, Camp-Specific A

Ensembl ID : ENSATEG00000019054
Gene Symbol: PDE4BA
2 Cross references
226 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSATEG00000016050
Gene Symbol: PDE4D
3 Cross references
222 Possible Orthologues:

Phosphodiesterase 5a, Cgmp-Specific, B

Ensembl ID : ENSATEG00000000026
Gene Symbol: PDE5AB
3 Cross references
210 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSATEG00000011609
Gene Symbol: PDE7A
3 Cross references
215 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSATEG00000005121
Gene Symbol: PDE9A
1 Cross references
192 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSATEG00000009334
Gene Symbol: PIK3R1
1 Cross references
203 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSATEG00000004078
Gene Symbol: PIK3R3
3 Cross references
188 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).